Accession Number: | 0001209191-20-028110 |
Date: | 2020-05-07 |
Issuer: | ADAPTIVE BIOTECHNOLOGIES CORP (ADPT) |
Original Submission Date: |
ROBINS CHAD M
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
1551 EASTLAKE AVE E STE 200
SEATTLE, WA 98102
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-05-07 | M | 45,000 | a | $0.33 | 1,923,180 | direct | ||
COMMON STOCK | 2020-05-07 | S | 36,186 | d | $35.47 | 1,886,994 | direct | ||
COMMON STOCK | 2020-05-07 | S | 8,814 | d | $36.13 | 1,878,180 | direct | ||
COMMON STOCK | 2020-05-07 | 0 | $0.00 | 500,000 f4 | indirect | ||||
COMMON STOCK | 2020-05-07 | 0 | $0.00 | 350,000 f4 | indirect |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 0.33 | 2020-05-07 | deemed execution date | M | 45,000 (d) | 2021-12-20 | common stock 45,000 | $0.33 | 601,560 | direct |
ID | footnote |
---|---|
f1 | these transactions reported in this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on november 22, 2019. |
f2 | the price reported for this transaction is a weighted-average price. the shares were sold in multiple transactions ranging from $35.00 to 35.99, inclusive. the reporting person undertakes to provide to adaptive biotechnologies corporation, any security holder of adaptive biotechnologies corporation, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this form 4. |
f3 | the price reported for this transaction is a weighted-average price. the shares were sold in multiple transactions ranging from $36.00 to 36.45, inclusive. |
f4 | the reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
f5 | the options are fully vested and exercisable. |